Omeros lays plans for $115M stock offering

Seattle-based Omeros has blueprinted plans for an IPO to raise $115 million. Omeros is betting that its experimental therapies for inflammation and CNS disorders can snag investors' dollars to complete a late-stage study of its lead drug. Omeros has burned through $72 million since it started in 1994 and had $27 million on hand as of last September. The Seattle Times notes that the filing comes after a rough year for IPOs, with more filings withdrawn last year than completed.

- see this release
- read the report from the Seattle Times

Related Articles:
Omeros to buy Nura in cash/stock deal. Report
Omeros gets new funding. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.